Skip directly to Accessibility Notice

PPH
VanEck Pharmaceutical ETF

Fund Description

VanEck Pharmaceutical ETF (PPH®) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS®US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well a production, marketing and sales of pharmaceuticals.

 
 

  • Fund Ticker

    PPH
  • Exchange

    NASDAQ
  • Inception Date

    12/20/2011
  • ETF Structure

    Physical
  • Administrator

    Van Eck Associates
  • Index Ticker

    MVPPHTR
  • Index Rebalancing

    Quarterly

 
as of 07/01/22

  • 30-Day SEC Yield

    1.68%
  • Total Net Assets

    $590.7M
  • Number of Holdings

    25
  • Options

    Available
  • Gross Expense Ratio2

    0.35%
  • Net Expense Ratio/TER2

    0.35%
  • Distribution Frequency

    Quarterly
  • Next Distribution Date

    09/30/2022

Morningstar™ Ratings3
as of 05/31/2022

Category Overall 3 Year 5 Year
Health
3 stars of 142 funds
4 stars of 142 funds
3 stars of 132 funds

Key Points

  • Highly Liquid Companies 
    Index seeks to track the most liquid companies in the industry based on market capitalization and trading volume

  • Industry Leaders
    Index methodology favors the largest companies in the industry

  • Global Scope 
    Portfolio may include both domestic and U.S. listed foreign companies, allowing for enhanced industry representation

Trading Information

  • Fund Ticker

    PPH
  • Index Total Return Ticker

    MVPPHTR
  • NAV

    PPHNV
  • Intraday NAV (IIV)4

    PPHIV
  • Shares Outstanding

    7,638,138
  • Estimated Cash

    PPHEU
  • Total Cash

    PPHTC
  • CUSIP

    92189F692
  • ISIN

    US92189F6925
Source: Bloomberg

Fees and Expenses2

  • Management Fee

    0.35%
  • Other Expenses

    --
  • Acquired Fund Fees and Expenses

    --
  • Gross Expense Ratio

    0.35%
  • Fee Waivers and
    Expense Reimbursement

    --
  • Net Expense Ratio/TER2

    0.35%

2'Van Eck Associates Corporation (the “Adviser”) will pay all expenses of the Fund, except for the fee payment under the investment management agreement, acquired fund fees and expenses, interest expense, offering costs, trading expenses, taxes and extraordinary expenses. Notwithstanding the foregoing, the Adviser has agreed to pay the offering costs until at least February 1, 2023.'

Investment Professionals

  • Portfolio Manager and Head of Equity ETFs
  • Oversees the Equity ETF Investment Management Team including development and management of index replication and optimization strategies
  • Joined VanEck in 2005
  • CFA charterholder; member of the CFA Society New York
  • BA, Mathematics and Economics, New York University
  • Portfolio Manager and Analyst for Equity ETFs
  • Joined VanEck in 2007
  • Prior to his current role, held a portfolio administration position at VanEck
  • Previously, Portfolio Analyst at Evaluation Associates
  • BS, Business Administration (concentration in Financial Analysis), State University of New York at Buffalo
  • Analyst for Equity ETFs
  • Joined VanEck in 2018
  • Prior to joining VanEck, ETF Basket Operations Analyst at JPMorgan
  • BS, Finance, Providence College
  • Analyst for Equity ETFs
  • Joined VanEck in 2019
  • Prior to VanEck, Intermediate Representative, Exchange Traded Funds at BNY Mellon.
  • BS, Accounting, Hunter College

Prices as of 07/01/22

NAV/
Market
Price
Volume
30-Day Avg./
Last Trading Day
Daily Change
NAV/
Last Price
YTD Change NAV/
Last Price
Premium/
Discount
30-Day
Median
Bid Ask
Spread
NAV
Chart
PPH $77.33
$77.26
214,365
180,655
$0.49 / +0.64%
$0.42 / +0.55%
+1.03%
+0.92%
$-0.07
-0.09%
0.03%

Premium/Discount History as of 07/01/22

Calendar Year 2021 3Q 2021 4Q 2021 1Q 2022 2Q 2022 Premium/Discount Charts NAV & Prem/Discount History
Days closed at a premium 146 36 41 29 30
PPH Days closed at NAV 24 5 8 9 7
Days closed at a discount 82 23 15 24 25

Performance History: Average Annual Total Returns* (%)

  1 MO 3 MO YTD 1 YR 3 YR 5 YR 10 YR LIFE
12/20/11
PPH (NAV) 2.10 5.15 3.49 11.71 15.14 8.61 10.27 10.07
PPH (Share Price) 2.17 5.20 3.50 11.74 15.15 8.61 10.28 10.17
MVPPHTR (Index) 2.07 5.14 3.44 11.44 14.84 8.44 10.17 9.96
Performance Differential (NAV - Index) 0.03 0.01 0.05 0.27 0.30 0.17 0.10 0.11
  1 MO 3 MO YTD 1 YR 3 YR 5 YR 10 YR LIFE
12/20/11
PPH (NAV) 5.24 3.58 3.58 17.62 11.51 9.66 9.80 10.25
PPH (Share Price) 5.35 3.64 3.64 17.57 11.53 9.69 9.82 10.36
MVPPHTR (Index) 5.22 3.53 3.53 17.27 11.19 9.47 9.68 10.13
Performance Differential (NAV - Index) 0.02 0.05 0.05 0.35 0.32 0.19 0.12 0.12

Top 10 Holdings (%) as of 05/31/22 Daily Holdings

Total Holdings: 25
Swipe
to view
full data
Holding Name
Ticker
Shares
Market Value
(US$)
% of Net
Assets
Eli Lilly & Co
LLY US
87,288
27,359,551 5.67
Merck & Co Inc
MRK US
294,881
27,137,898 5.63
Bristol-Myers Squibb Co
BMY US
336,695
25,403,638 5.27
Novartis Ag
NVS US
279,235
25,393,631 5.27
Astrazeneca Plc
AZN US
379,600
25,235,808 5.23
Pfizer Inc
PFE US
470,544
24,957,654 5.17
Mckesson Corp
MCK US
74,663
24,540,981 5.09
Viatris Inc
VTRS US
1,990,806
24,427,190 5.06
Johnson & Johnson
JNJ US
135,444
24,316,261 5.04
Novo Nordisk A/S
NVO US
218,337
24,104,405 5.00
Top 10 Total (%) 52.43
These are not recommendations to buy or to sell any security. Securities and holdings may vary.

Country Weightings (%) as of 05/31/22

  • Country

    % of Net Assets
  • United States

    66.81
  • United Kingdom

    9.78
  • Switzerland

    5.27
  • Denmark

    5.00
  • France

    4.88
  • Japan

    4.28
  • Israel

    3.68
  • Ireland

    0.22
  • Other/Cash

    0.09

Sector Weightings (%) as of 05/31/22

  • Sector

    % of Net Assets
  • Health Care

    99.9
  • Other/Cash

    0.1